Ketamine Treatment Plans for Chronic Conditions

This observational cohort study (n=500) conducted by the RIVER Foundation aims to understand the safety and efficacy of home ketamine treatment plans for chronic conditions, including chronic pain, depressive disorders, anxiety disorders, and other chronic conditions.

Ketamine, administered through various routes such as IV, IM, SubQ, and Sublingual, is being studied within the context of different treatment modalities including psychotherapy, music therapy, and acutherapy. The study seeks to determine how these adjunct therapies affect the outcomes of ketamine treatments.

Additionally, the study will focus on assessing the impact of ketamine treatments on suicidal ideation, a multifaceted issue often associated with chronic conditions such as depression, pain, and anxiety.

Participants, aged 18 and older, with identifiable chronic conditions requiring mental health or pain management, are eligible to participate. Exclusion criteria include healthy individuals.

Primary outcome measures include assessing the acceptability of ketamine route of use and measuring participants’ mental health using scales such as the Patient Health Questionnaire-9 (PHQ9), Generalized Anxiety Disorder-7 (GAD7), and Posttraumatic Stress Disorder Checklist (PCL-5).

The study started on January 1, 2023, with an estimated primary completion date of January 1, 2024, and an estimated completion date of June 1, 2024. It is conducted at RIVER Telehealth in Helena, Montana, United States.

Topic Pain Depression Anxiety Suicidality PTSD
Compound Ketamine
Country United States of America
Visit trial
Status Recruiting
Results Published No
Start date 01 January 2023
End date 01 June 2024
Phase Not Applicable
Design Open
Type Observational
Generation First
Participants 500
Sex All
Age 18- 99
Therapy Yes

Trial Details

A study aimed to assess the efficacy of the various approaches to prescribing Ketamine currently in use off-label. The focus will be to include ketamine within the study plan of those with chronic conditions who are receiving ketamine.

Trial Number NCT06038409

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.